Direct access to high-purity chemical APIs synthesized under multi-ton CDMO capacity, providing immediate batch availability, HPLC purity validation, and regulatory technical packages.
Dulaglutide (CAS NO: 923950-08-7)
Costa Rica GMP Incretin Supply & Pricelist
Custom Orforglipron (CAS: 2212020-52-3)
Non-Peptidic GLP-1R Small Molecule Reference
Cargrilintide (CAS: 1415456-99-3)
Metabolic Synergist & Dual-Agonist Research
Deslorelin (CAS: 57773-65-6)
Potent GnRH Agonist for Veterinary & Human R&D
Costa Rica has solidified its standing as Latin America’s undisputed focal point for advanced life sciences and medical technology manufacturing. Driven by the targeted pro-investment architecture of PROCOMER (Promotora del Comercio Exterior de Costa Rica) and the high-tech industrial ecosystems within the Coyol Free Zone, Innova Park, and the El Barreal Industrial Complex in Heredia and Alajuela, the nation is rapidly advancing beyond precision medical device assembly into high-value biopharmaceutical formulation, sterile fill-finish operations, and clinical contract research. Within this evolving technological landscape, Glucagon-Like Peptide-2 (GLP-2) analogues have surfaced as critical strategic active pharmaceutical ingredients (APIs).
Endogenous GLP-2 is a 33-amino acid proglucagon-derived peptide produced by neuroendocrine L-cells in the ileum and colon, possessing pronounced intestinotrophic properties. Synthetic and semi-synthetic GLP-2 analogues—most notably Teduglutide ([Gly2]GLP-2), alongside next-generation extended half-life assets like Apraglutide and Glepaglutide—represent life-sustaining interventions for severe gastrointestinal impairment. Specifically, in indications such as Short Bowel Syndrome (SBS) resulting from surgical resection, congenital malformations, vascular infarction, or refractory Crohn's disease, GLP-2 analogues stimulate mucosal hyperplasia, upregulate crypt cell proliferation, elevate villus height, reduce intestinal permeability, and profoundly improve mucosal fluid and macronutrient absorption. For the Costa Rican national healthcare system—governed institutionally by the Caja Costarricense de Seguro Social (CCSS)—as well as private hospital networks like Hospital CIMA, Clínica Bíblica, and Hospital Metropolitano, securing access to economical, cGMP-certified GLP-2 peptide bulk APIs has become a procurement priority to mitigate the exorbitant economic burden of lifelong parenteral nutrition (PN) and intravenous fluid dependence.
Global pharmaceutical corporations operating under Costa Rica's Free Zone Regime (Ley de Régimen de Zonas Francas) require high-purity, DMF-supported lyophilized peptide APIs for advanced fill-finish lines, clinical supply formulation, and Central American re-export.
Costa Rica’s socialized healthcare authority spends tens of millions annually managing chronic gut failure. Procuring cost-efficient generic GLP-2 peptide APIs dramatically lowers systemic intensive care overhead and patient hospitalization days.
Western reliance on fragmented peptide synthesizers has exposed vulnerabilities in raw material access. Our automated solid-phase capacity in Hangzhou guarantees continuous multi-kilogram commercial continuity for international buyers.
The synthesis of GLP-2 analogues presents unique chemical complexity that challenges conventional small-molecule or standard short-chain peptide manufacturers. Native human GLP-2 and modified therapeutic sequences like Teduglutide are 33-mer linear peptides (molecular weight ~3752.1 g/mol). Their assembly involves hydrophobic stretches and aggregation-prone sequences—specifically within the central and C-terminal domains—which frequently trigger severe secondary structure formation (β-sheet aggregation) during chain elongation. Traditional European and North American CDMOs often struggle with low coupling yields, extensive deletion sequences (such as des-Gly2 or truncated fragments), and exorbitant raw material costs, culminating in prohibitively high market prices exceeding $12,000 to $18,000 per gram for cGMP material.
At our specialized manufacturing hub in Hangzhou, China, we have resolved these scale-up bottlenecks by utilizing proprietary Hybrid Solid-Phase Peptide Synthesis (SPPS) and Liquid-Phase Fragment Condensation (LPPS) technologies. Leveraging high-load, low-swelling resins (such as PEG-grafted polystyrenes or 2-chlorotrityl chloride resins), fully automated microwave-assisted coupling protocols, and advanced pseudoproline dipeptide building blocks, our facilities eliminate chain aggregation in real-time. This structural mastery produces crude purities exceeding 85%, significantly minimizing downstream preparative reverse-phase HPLC passes, reducing organic solvent waste (green chemistry compliance), and delivering a 40% to 65% cost-arbitrage advantage directly to pharmaceutical formulators in Costa Rica and international procurement networks.
Every batch dispatched to Costa Rican analytical laboratories, university consortia (UCR, TEC), and pharmaceutical repackaging facilities is accompanied by complete regulatory documentation.
| Analytical Parameter | Testing Methodology | Release Specification (cGMP Grade) | Commercial Impact |
|---|---|---|---|
| Identity Verification | High-Resolution LC-MS (ESI-TOF) + Amino Acid Analysis (AAA) | Monoisotopic Mass: 3750.0 ± 1.0 Da; Conforms to theoretical sequence | Guarantees zero sequence error or structural isomer drift. |
| Chromatographic Purity | Reversed-Phase HPLC (UV @ 214nm / 280nm) | ≥ 98.5% (Clinical) / ≥ 99.2% (Commercial Injectable) | Minimizes immunogenic peptide aggregates and related substances. |
| Counter-Ion Balancing | Ion Chromatography (IC) / Enzymatic Quantification | Acetate content: ≤ 10.0%; TFA residue: ≤ 0.1% (or undetectable) | Critical for biocompatibility and physiological pH formulation. |
| Bacterial Endotoxins | Kinetic Turbidimetric / Chromogenic LAL Assay | < 5.0 EU/mg (Custom injectable grade: < 1.0 EU/mg) | Complies with USP <85> & EP guidelines for parenterals. |
| Residual Solvents | Headspace Gas Chromatography (GC-MS/FID) | ICH Q3C guidelines (Acetonitrile, DMF, DCM, Piperidine < limits) | Zero toxic processing solvent retention in active drug substance. |
| Peptide Net Content | Nitrogen Elemental Analysis (Dumas Method) | ≥ 80.0% to 90.0% (Balance: counter-ion & bound water) | Enables exact milligram-level dosing calculation for clinical dosage forms. |
Transparent reference pricing for pharmaceutical developers, academic institutions, and commercial fill-finish operators in San José, Cartago, and the Alajuela life sciences cluster.
| Target Sequence / Analogue | CAS Number | Grade / Quality Standard | Packaging Tier | Estimated CIF San José (USD) | Availability / Lead Time |
|---|---|---|---|---|---|
| Teduglutide Reference Standard | 197922-42-2 | Analytical Assay Standard (≥ 98.0%) | 100 mg / 1 gram | $280 – $650 / vial | In Stock (3-5 Days) |
| Teduglutide Acetate (R&D Tier) | 197922-42-2 | Pre-clinical Research (≥ 95.0%, TFA-free) | 10 grams – 50 grams | $1,850 / 10g package | In Stock (Express Air) |
| Teduglutide Bulk (Pilot Scale) | 197922-42-2 | High Purity (≥ 98.5%, Low Endotoxin) | 100 grams – 500 grams | $12,500 / 100g tier | 10-14 Business Days |
| Commercial cGMP Teduglutide API | 197922-42-2 | Commercial Injectable Grade (≥ 99.0%) | 1 kg to Multi-Kg Drum | Direct RFQ / Custom Quote | Batch Production / Campaign |
| Apraglutide Synthetic Peptide | 1429545-20-7 | Pre-clinical / R&D Grade (≥ 97.0%) | 1 gram / 10 grams | $650 / gram (Tiered) | Synthesis: 2 Weeks |
| Glepaglutide Research Sequence | 1616460-70-0 | Bioanalytical Purity (≥ 98.0%) | 5 grams – 25 grams | $780 / gram | Synthesis: 2-3 Weeks |
| GLP-1/GLP-2 Co-Agonist Leads | Custom Sequence | Custom Synthesis (≥ 95.0% - 99.0%) | Custom Batch Formulation | Quoted upon sequence review | Custom CDMO Pipeline |
*Notice: Listed rates reflect FOB/CIF baseline projections for the Costa Rica territory subject to volume commitments, counter-ion specification (Acetate vs. Hydrochloride), and regulatory document filing requirements (e.g., USDMF, EDMF, or Open Part dossier delivery).
Successfully importing biopharmaceutical APIs and lyophilized peptide substances into Costa Rica requires exact conformity with Ministerio de Salud de Costa Rica (Ministry of Health) regulations. Pharmaceutical active substances entering through Aeropuerto Internacional Juan Santamaría (SJO) or Puerto Caldera must clear rigorous customs protocols under the Technical Drug Regulation (Reglamento Técnico de Registro, Control y Fiscalización de Medicamentos).
For biomanufacturing entities located inside designated Zonas Francas (such as Alajuela or Cartago), peptide APIs are processed under specialized simplified transit declarations. Thinheal collaborates with leading freight forwarders (DHL Medical Express, World Courier, FedEx Life Science) using validated IATA-compliant temperature-controlled air packaging. Shipments are maintained at -20°C (or dry ice at -78.5°C for sensitive liquid conjugates) with calibrated continuous temperature loggers (e.g., TempTale or Sensitech devices) providing traceable cold-chain proof from our Hangzhou lyophilization facility to the client’s receiving isolator in Costa Rica.
To support formal drug product registration with the Dirección de Regulación de Productos de Interés Sanitario, Thinheal provides comprehensive regulatory dossiers conforming to the ICH Common Technical Document (CTD) format:
In addition to GLP-2 analogues, our Hangzhou synthesis facility delivers commercial quantities of multi-receptor incretin mimetics, melanocortin agonists, and regenerative therapeutic peptides.
Mazdutide (CAS: 2259884-03-0)
Dual GCG/GLP-1 Receptor Agonist for Costa Rica Studies
Tirzepatide (CAS: 2023788-19-2)
High-Yield Dual Incretin Commercial Manufacturing
Custom Setmelanotide (CAS: 920014-72-8)
Oligogenic Metabolic MC4R Agonist Sequence
Bremelanotide PT-141 (CAS: 189691-06-3)
Synthetic Melanocortin Receptor Active Compound
Custom Survodutide (CAS: 2805997-46-8)
Dual Glucagon/GLP-1 Receptor Agonist for MASH
Dulaglutide Commercial (CAS: 923950-08-7)
Bulk Manufacturing & Large-Scale Central America Supply
BPC-157 (CAS: 137525-51-0)
Gastric Pentadecapeptide for Mucosal Repair R&D
Eptifibatide (CAS NO: 188627-80-7)
Cardiovascular Antiplatelet Cyclic Peptide API
Expert insights addressing regulatory clearance, molecular characterization, and procurement logistics for Costa Rican and multinational pharmaceutical teams.
While both peptides originate from proglucagon cleavage, their physiological receptors, tissue distributions, and clinical indications are distinctly divergent. GLP-1 analogues (such as Semaglutide, Tirzepatide, and Dulaglutide) bind selectively to the GLP-1 receptor (GLP-1R) located primarily in pancreatic β-cells, gastric mucosa, and central nervous system appetite centers, modulating glucose-dependent insulin secretion, delaying gastric emptying, and suppressing appetite for Type 2 Diabetes and obesity management.
In stark contrast, GLP-2 analogues (such as Teduglutide and Apraglutide) bind specifically to the G-protein coupled GLP-2 receptor (GLP-2R), predominantly expressed in enteric neurons, subepithelial myofibroblasts, and enteroendocrine cells of the gastrointestinal tract. Activation induces local release of intestinal growth factors (notably IGF-1 and ErbB ligands), provoking robust villus lengthening, crypt depth expansion, reduced enterocyte apoptosis, and augmented nutrient/fluid absorption. GLP-2 analogues are clinically approved or investigated for Short Bowel Syndrome (SBS), necrotizing enterocolitis, gastrointestinal mucosal mucositis induced by intensive chemotherapy, and inflammatory bowel disease (IBD) complications.
During standard solid-phase peptide synthesis (SPPS), trifluoroacetic acid (TFA) is ubiquitously employed for the final cleavage of the peptide from the resin and subsequent global deprotection of amino acid side chains. However, residual trifluoroacetate counter-ions are biologically undesirable and potentially cytotoxic in parenterally administered clinical formulations.
At our Hangzhou facility, commercial-grade GLP-2 analogues undergo a dedicated two-stage ion-exchange chromatography step using hydrophilic polymeric resins or dynamic counter-current diafiltration against dilute acetic acid or ammonium acetate solutions. Our standard cGMP release specifications guarantee residual TFA levels below 0.1% (w/w)—often below the analytical limit of detection (LOD) via 19F-NMR or ion chromatography—yielding high-affinity, bio-compatible acetate salt forms with exceptionally stable lyophilized reconstitution profiles.
For pharmaceutical clients and university laboratories registering or formulating peptide therapeutics in Costa Rica, we furnish a comprehensive regulatory submission binder containing:
For standard catalogue GLP-2 analogues (such as Teduglutide reference standard or research grade, CAS 197922-42-2) maintained in our cold-storage inventory, dispatch occurs within 48 hours of order confirmation. Express cold-chain transit from Hangzhou International Airport (HGH) or Shanghai Pudong (PVG) to San José Juan Santamaría Airport (SJO) via specialized life science temperature-controlled carriers takes approximately 4 to 7 business days.
For commercial campaign syntheses, custom sequences, or multi-kilogram cGMP batches requiring full validation, production lead times generally range between 4 to 8 weeks, inclusive of synthetic assembly, continuous RP-HPLC purification, salt-exchange lyophilization, and exhaustive release testing.
The substantial economic efficiency achieved by our Hangzhou manufacturing ecosystem is the result of vertical integration across the complete peptide value chain. China produces over 70% of the world's upstream raw materials for peptide synthesis, including Fmoc-protected amino acids, specialized coupling reagents (HBTU, HATU, PyBOP), and high-performance cross-linked polystyrene resins.
By eliminating cross-border component shipping tariffs, deploying proprietary high-throughput automated synthesis reactors capable of multi-ton annual chemical output, and optimizing energy-efficient solvent recovery loops, Thinheal delivers identical or superior cGMP purity profiles at a 40% to 65% reduction in landed price compared to Western European or North American peptide suppliers. This enables institutional payers like Costa Rica's CCSS to maximize their budgetary impact without compromising patient safety or clinical efficacy.
Require custom amino acid modifications, lipid conjugates, or commercial volume validation?
Send Inquiry Now
Thin